<DOC>
	<DOCNO>NCT01082367</DOCNO>
	<brief_summary>This study investigate efficacy inhaled TOBI treatment early infection P. aeruginosa paediatric patient cystic fibrosis .</brief_summary>
	<brief_title>Randomized , Controlled Study CF Patients Between 3 Months Less Than 7 Years</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Diagnosis cystic fibrosis Early low respiratory tract infection P. aeruginosa , Known local systemic hypersensitivity aminoglycosides inhale antibiotic . Administration loop diuretic within 7 day prior study drug administration . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Tobramycin Inhalation solution</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Lung disease</keyword>
	<keyword>anti-bacterial agent</keyword>
</DOC>